Johnson & Johnson (NYSE: JNJ) is seeing quick uptake of its oral plaque psoriasis therapy Icotyde in U.S. dermatology practices. New independent physician research reports Icotyde prescriptions are building momentum and gaining share within the oral advanced therapy segment. Surveyed dermatologists indicate…
Interested in Oruka Therapeutics, Inc.? Here are five stocks we like better. ORKA-001's 600-milligram regimen achieved a 61% PASI 100 complete-clearance rate and an 86% PASI 90 response rate at week 16 in the Phase IIb EVERLAST-B psoriasis study. Lower-dose regimens produced PASI 100 rates…
By Editorial Staff 29th October 2026 0 The Psoriasis Area and Severity Index (PASI) measures cutaneous disease severity and treatment response but does not directly assess symptoms, functional impairment, quality of life or psychological morbidity. NICE and European guidelines recommend assessing these additional…
Oruka Therapeutics (ORKA) reported positive Phase 2b results showing that its experimental drug ORKA-001 demonstrated high rates of skin clearance in patients with moderate-to-severe plaque psoriasis, according to data from the EVERLAST-B study. At Week 16, patients receiving the high 600 mg dose…
Delgocitinib poster presentations will include new data from the Phase 3 DELTA TEEN Trial as well as findings from a wide range of health economics and outcomes research and real-world evidence1-9 Multiple poster presentations will feature new data on real-world clinical characteristics…
Drugmaker AbbVie Inc. (ABBV) announced Tuesday that Health Canada has approved SKYRIZI (risankizumab) to treat children with moderate to severe plaque psoriasis. The treatment will be given for pediatric patients aged 6 to Separately, AbbVie announced a multi-year partnership with McLaren…
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Icotyde (icotrokinra hydrochloride) to treat moderate-to-severe plaque psoriasis in adults and adolescents aged 12 years and older who weigh at least 40kg and are candidates for systemic therapy. Plaque psoriasis is an…
This can be especially helpful for Black people because psoriasis may look different on darker skin. Patches may appear purple, dark brown, or gray instead of red or pink. Dark or light spots may also remain after the skin clears.
The atopic dermatitis results were presented at the Aging Research and Drug Discovery (ARDD) conference in Boston on October 2. Clinical findings from the AK program were presented in a late-breaking presentation at the European Academy of Dermatology and Venereology (EADV)…
Researchers at Biohub, an organisation backed by the Chan Zuckerberg Initiative co-founded by Priscilla Chan, have identified potential new drug targets for psoriasis by combining AI with genetic screening. The study, published in Nature Communications, discovered 2 biological pathways that could…
Psoriasis: biologic drugs and new pills, treatment of plaque psoriasis and life with the disease.
An article joins this feed when it matches these terms. Each one is also a search of its own.